Shares of ResMed Inc. RMD slumped 0.35% to $228.69 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.43% to 5,881.63 and Dow ...

ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

These 2 ASX shares are set to deliver a strong set of earnings in the next quarter according to experts. Let's dive in.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

The contact-free sleep monitoring systems market is projected to grow at an 8.1% CAGR, reaching $214.7 million by 2033 from ...

Nyxoah's disrupting Genio implant is likely to revolutionize Obstructive Sleep Apnea, and FDA's decision is expected in Q1 ...

Shares of ResMed Inc. RMD inched 0.56% higher to $233.88 Thursday, on what proved to be an all-around mixed trading session ...

Shares of ResMed Inc. (NYSE:RMD – Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $237.27, but opened at $230.21. ResMed shares last traded at $226 ...

Honda and Nissan begin merger talks with a plan for the combination to be completed in 2026, Qualcomm scores a victory in its licensing dispute with Arm Holdings, and the FDA approves Eli Lilly’s ...

Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...

Chip stocks advanced, led by Broadcom ( AVGO) after UBS analysts raised their price target for the stock, citing the ...

The FDA approved Eli Lilly's (LLY) obesity drug for the treatment of sleep apnea, sending rival ResMed (RMD) stock lower ...